P962: CHANGE IN SOLUBLE BCMA LEVEL MAY BE A SURROGATE MARKER OF EARLY RESPONSE TO THERAPY IN PATIENTS WITH RELAPSED/REFRACTORY MULTIPLE MYELOMA (RRMM): PRELIMINARY RESULTS FROM A PHASE I STUDY OF CEVOSTAMAB

Detalles Bibliográficos
Autores principales: Nakamura, R., Hendricks, R., Dokhaei, R., Susilo, M., Wilson, D., Trudel, S., Cohen, A., Harrison, S. J., Krishnan, A., Fonseca, R., Adamkewicz, J. I., Li, M., Wong, C., Cooper, J., Sumiyoshi, T.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Lippincott Williams & Wilkins 2022
Materias:
Posters
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9430057/
http://dx.doi.org/10.1097/01.HS9.0000846716.90763.d0

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9430057/
http://dx.doi.org/10.1097/01.HS9.0000846716.90763.d0

Ejemplares similares